Floatz logo

Rituximab

Indolent B-Cell Non-Hodgkin Lymphoma

Explore 38 assets in Indolent B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
BB67/100
Confidence
Indicative
v0.2
Sponsor
Fox Chase Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05934097CT.gov
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
—Withdrawn———
NCT05217914CT.gov
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
—Completed———
NCT05265975CT.gov
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
—Terminated———
NCT05073250CT.gov
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
—Unknown———
NCT05025800CT.gov
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT04883437CT.gov
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
—Recruiting———
NCT04323956CT.gov
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
—Active Not Recruiting———
NCT04136756CT.gov
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
—Completed———
NCT03884998CT.gov
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT03625037CT.gov
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
—Active Not Recruiting———
Show 9 more trials
NCT03571568CT.gov
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
—Recruiting———
NCT02384954CT.gov
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
—Terminated———
NCT02362035CT.gov
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
—Completed———
NCT02086175CT.gov
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
—Completed———
NCT01933516CT.gov
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
—Completed———
NCT01732913CT.gov
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
—Terminated———
NCT01732926CT.gov
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
—Terminated———
NCT00089284CT.gov
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
—Terminated———
NCT00129090CT.gov
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Indolent B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
Rituximab (this asset)Fox Chase Cancer CenterP3BB · 67
CyclophosphamideInstitute of Hematology & Blood Diseases Hospital, ChinaP2BB
FludarabineInstitute of Hematology & Blood Diseases Hospital, ChinaP3BB
PembrolizumabUniversity of WashingtonP2BB
Vaccin Genhevac B PasteurCentral Hospital, Nancy, FranceP4BB
IbrutinibSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP3BB
Cyclosporin AFred Hutchinson Cancer CenterP3BB
Polatuzumab VedotinUniversity of WashingtonP2BB
AcalabrutinibEmory UniversityP2BB

+42 more in the Indolent B-Cell Non-Hodgkin Lymphoma cohort

Other indications for Rituximab

IndicationSponsorPhaseRating
Lymphoblastic Lymphoma—P4BBB · 75
Grade III Lymphomatoid Granulomatosis—P2BBB · 74
Testicular Lymphoma—P2BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Rituximab in Indolent B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-indolent-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →